低剂量白细胞介素-2治疗活动性系统性红斑狼疮(LUPIL-2):一项多中心、双盲、随机、安慰剂对照II期试验
主要终点SRI-4应答率在意向治疗人群中未达统计学显著(ILT-101组68% vs 安慰剂组58%,p=0.3439),原因在于保加利亚两个中心的安慰剂组SRI-4应答率为100%。排除这两个中心患者的预设人群事后符合方案分析(n=53)显示SRI-4应答率差异有统计学意义(ILT-101组83.3% vs 安慰剂组51.7%,p=0.0168),两项关键次要终点亦如此。
要点
- 意向治疗人群主要终点未达:ILT-101组SRI-4应答68% vs 安慰剂组58%(p=0.3439)。
- 排除保加利亚两中心后符合方案人群(n=53)SRI-4应答ILT-101组83.3% vs 安慰剂组51.7%(p=0.0168)。
- ILT-101耐受良好,未产生抗药抗体。
核心结论
- 对主要和关键次要终点在符合方案人群中进行的事后分层分析,辅以多个其他次要终点的探索性分析,支持低剂量IL-2对活动性SLE有益。
研究设计与样本
- 多中心、双盲、随机、安慰剂对照II期概念验证试验,100例接受标准治疗且疾病活动中至重度的SLE患者按1:1随机分配。
- 第12周按预设分层分析评估疗效:主要终点为SRI-4应答,关键次要终点为SELENA-SLEDAI评分的相对变化和绝对变化。
主要发现
- 意向治疗人群主要终点未达:ILT-101组SRI-4应答68% vs 安慰剂组58%(p=0.3439),原因为保加利亚两个中心安慰剂组SRI-4应答率为100%。
- 排除上述两中心的预设人群事后符合方案分析(n=53)显示SRI-4应答率ILT-101组83.3% vs 安慰剂组51.7%(p=0.0168),差异有统计学意义。
- 同一事后符合方案分析中两项关键次要终点亦显示统计学显著差异,并伴有多个次要探索性终点的差异。
- ILT-101耐受良好,未产生抗药抗体。
关键数值与推荐
- 主要终点SRI-4应答:ILT-101组68% vs 安慰剂组58%(p=0.3439),意向治疗人群未达统计学显著。
- 事后符合方案人群(n=53)SRI-4应答:ILT-101组83.3% vs 安慰剂组51.7%(p=0.0168),差异有统计学意义。
临床怎么用
- 原文未据此给出推荐。
局限性
- 主要终点在意向治疗人群未达统计学显著,原文将其归因于保加利亚两个中心安慰剂组SRI-4应答率达100%。
- 支持低剂量IL-2有益的结论基于排除上述两中心患者后的预设人群事后符合方案分析(n=53)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: A regulatory T cell (Treg) insufficiency due to shortage of interleukin-2 (IL-2) is central to the pathophysiology of systemic lupus erythematosus (SLE). We performed a multicentre, double-blinded, randomised, placebo-controlled phase II proof-of-concept trial to evaluate the efficacy of low-dose IL-2 therapy in patients with SLE having moderate-to-severe disease activity while receiving standard treatment. METHODS: We randomly assigned 100 patients in a 1:1 ratio to receive either 1.5 million IU/day of subcutaneous IL-2 (ILT-101) or placebo for 5 days followed by weekly injections for 12 weeks. Clinical efficacy was assessed at week 12 in a predefined hierarchical analysis of (1) the SLE responder index-4 (SRI-4) response as a primary end point, and of (2) relative and (3) absolute changes in the Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index scores as key secondary end points. RESULTS: The primary end point was not met in the intention-to-treat population (ILT-101: 68%, placebo: 58%; p=0.3439), due to a 100% SRI-4 response rate in the placebo group from the two sites from Bulgaria. A post hoc per-protocol analysis on a prespecified population that excluded patients from these two sites (n=53) showed a statistically significant difference for the SRI-4 response rate (ILT-101: 83.3%; placebo: 51.7%; p=0.0168), and for the two key secondary end points, accompanied by differences in several secondary exploratory end points. ILT-101 was well tolerated and there was no generation of antidrug antibodies. CONCLUSIONS: The post hoc hierarchical analysis of the primary and key secondary end points in a per-protocol population, complemented by the exploratory analyses of multiple other secondary end points, support that low-dose IL-2 is beneficial in active SLE. TRIAL REGISTRATION NUMBER: NCT02955615.
引用
- Humrich JY, Cacoub P, Rosenzwajg M, et al. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann Rheum Dis. 2022. PMID: 35973803. doi:10.1136/ard-2022-222501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。